Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2017

  • ID: 4315542
  • Report
  • 112 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arbor Pharmaceuticals LLC
  • Bayer AG
  • BioApex sro
  • Biogen Inc
  • Evgen Pharma Plc
  • Ixchel Pharma LLC
  • MORE
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2017

Summary:

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 36 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Ophthalmology, Toxicology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Psoriasis, Friedreich Ataxia, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Cardiomyopathy, Chagas Disease (American Trypanosomiasis), Chronic Obstructive Pulmonary Disease (COPD), Diabetic Complications, Diabetic Nephropathy, Medulloblastoma, Neuroblastoma, Radiodermatitis, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Cerebral Vasospasm, Chronic Kidney Disease (Chronic Renal Failure), Corneal Degeneration, Encephalomyelitis, Huntington Disease, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Metastatic Breast Cancer, Metastatic Melanoma, Mitochondrial Diseases, Neuro Muscular Disorders, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Radiation Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
  • The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arbor Pharmaceuticals LLC
  • Bayer AG
  • BioApex sro
  • Biogen Inc
  • Evgen Pharma Plc
  • Ixchel Pharma LLC
  • MORE
  1. Introduction
  2. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview
  3. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development
  14. Arbor Pharmaceuticals LLC
  15. Bayer AG
  16. BioApex sro
  17. Biogen Inc
  18. C4X Discovery Holdings PLC
  19. Catabasis Pharmaceuticals Inc
  20. Daiichi Sankyo Company Ltd
  21. Evgen Pharma Plc
  22. Ixchel Pharma LLC
  23. Jiangsu Hengrui Medicine Co Ltd
  24. Mochida Pharmaceutical Co Ltd
  25. Reata Pharmaceuticals Inc
  26. Rigel Pharmaceuticals Inc
  27. vTv Therapeutics Inc
  28. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles
  29. BA-1521 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. bardoxolone methyl - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. CAT-4001 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. DH-404 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. dimethyl fumarate DR - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. IXC-103 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. IXC-105 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. LH-503 - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. LH-526 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. MG-132 - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. MIND-4 - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. monosodium luminol - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. nifurtimox - Drug Profile
  78. Product Description
  79. Mechanism Of Action
  80. R&D Progress
  81. nifurtimox SR - Drug Profile
  82. Product Description
  83. Mechanism Of Action
  84. R&D Progress
  85. omaveloxolone - Drug Profile
  86. Product Description
  87. Mechanism Of Action
  88. R&D Progress
  89. R-970 - Drug Profile
  90. Product Description
  91. Mechanism Of Action
  92. R&D Progress
  93. RS-9 - Drug Profile
  94. Product Description
  95. Mechanism Of Action
  96. R&D Progress
  97. RTI-79 - Drug Profile
  98. Product Description
  99. Mechanism Of Action
  100. R&D Progress
  101. SFX-01 - Drug Profile
  102. Product Description
  103. Mechanism Of Action
  104. R&D Progress
  105. SFX-02 - Drug Profile
  106. Product Description
  107. Mechanism Of Action
  108. R&D Progress
  109. SFX-03 - Drug Profile
  110. Product Description
  111. Mechanism Of Action
  112. R&D Progress
  113. Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
  114. Product Description
  115. Mechanism Of Action
  116. R&D Progress
  117. Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
  118. Product Description
  119. Mechanism Of Action
  120. R&D Progress
  121. Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
  122. Product Description
  123. Mechanism Of Action
  124. R&D Progress
  125. Small Molecule to Target NRF2 and BACH1 for Parkinson’s Disease - Drug Profile
  126. Product Description
  127. Mechanism Of Action
  128. R&D Progress
  129. Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile
  130. Product Description
  131. Mechanism Of Action
  132. R&D Progress
  133. Small Molecules to Activate NRF-2 for COPD - Drug Profile
  134. Product Description
  135. Mechanism Of Action
  136. R&D Progress
  137. Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile
  138. Product Description
  139. Mechanism Of Action
  140. R&D Progress
  141. Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease - Drug Profile
  142. Product Description
  143. Mechanism Of Action
  144. R&D Progress
  145. TBE-31 - Drug Profile
  146. Product Description
  147. Mechanism Of Action
  148. R&D Progress
  149. TFM-735 - Drug Profile
  150. Product Description
  151. Mechanism Of Action
  152. R&D Progress
  153. trigonelline hydrochloride - Drug Profile
  154. Product Description
  155. Mechanism Of Action
  156. R&D Progress
  157. VCB-101 - Drug Profile
  158. Product Description
  159. Mechanism Of Action
  160. R&D Progress
  161. VCB-102 - Drug Profile
  162. Product Description
  163. Mechanism Of Action
  164. R&D Progress
  165. VEDA-1209 - Drug Profile
  166. Product Description
  167. Mechanism Of Action
  168. R&D Progress
  169. XP-23829 - Drug Profile
  170. Product Description
  171. Mechanism Of Action
  172. R&D Progress
  173. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products
  174. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products
  175. Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones
  176. Featured News & Press Releases
  177. Jun 01, 2017: Reata Pharmaceuticals Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich's Ataxia
  178. Apr 24, 2017: TECFIDERA Data Demonstrates Improved Outcomes with Early MS Treatment at American Academy of Neurology in Boston
  179. Apr 18, 2017: Biogen Highlights Data on TECFIDERA at AAN Congress
  180. Mar 31, 2017: Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen
  181. Mar 28, 2017: Evgen Pharma: Further US Patent Grant
  182. Feb 23, 2017: Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
  183. Feb 14, 2017: Evgen Pharma Announces Patent Grant in the United States
  184. Feb 13, 2017: Evgen Pharma Announces Services Agreement with Drug Development Consortium
  185. Jan 17, 2017: Evgen Pharma Announces First Patient Dosed in Phase II Breast Cancer Trial
  186. Jan 11, 2017: Evgen Pharma Receives Positive DSMB Review of SAS Trial
  187. Nov 29, 2016: Hardman Research: Clinical potential of sulforaphane
  188. Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day
  189. Nov 16, 2016: New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
  190. Nov 15, 2016: Bayer to Fight Chagas Disease in Children
  191. Nov 14, 2016: Reata Announces Plan for Global Phase 2/3 Trial in Chronic Kidney Disease Caused by Alport Syndrome
  192. Appendix
  193. Methodology
  194. Coverage
  195. Secondary Research
  196. Primary Research
  197. Expert Panel Validation
  198. Contact Us
  199. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Products under Development by Companies, H1 2017 (Contd..3), H1
  11. Number of Products under Investigation by Universities/Institutes, H1
  12. Products under Investigation by Universities/Institutes, H1
  13. Products under Investigation by Universities/Institutes, H1 2017 (Contd..1), H1
  14. Number of Products by Stage and Mechanism of Actions, H1
  15. Number of Products by Stage and Route of Administration, H1
  16. Number of Products by Stage and Molecule Type, H1
  17. Pipeline by Arbor Pharmaceuticals LLC, H1
  18. Pipeline by Bayer AG, H1
  19. Pipeline by BioApex sro, H1
  20. Pipeline by Biogen Inc, H1
  21. Pipeline by C4X Discovery Holdings PLC, H1
  22. Pipeline by Catabasis Pharmaceuticals Inc, H1
  23. Pipeline by Daiichi Sankyo Company Ltd, H1
  24. Pipeline by Evgen Pharma Plc, H1
  25. Pipeline by Ixchel Pharma LLC, H1
  26. Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1
  27. Pipeline by Mochida Pharmaceutical Co Ltd, H1
  28. Pipeline by Reata Pharmaceuticals Inc, H1
  29. Pipeline by Rigel Pharmaceuticals Inc, H1
  30. Pipeline by vTv Therapeutics Inc, H1
  31. Dormant Products, H1
  32. Dormant Products, H1 2017 (Contd..1), H1
  33. Dormant Products, H1 2017 (Contd..2), H1
  34. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Arbor Pharmaceuticals LLC
  • Bayer AG
  • BioApex sro
  • Biogen Inc
  • C4X Discovery Holdings PLC
  • Catabasis Pharmaceuticals Inc
  • Daiichi Sankyo Company Ltd
  • Evgen Pharma Plc
  • Ixchel Pharma LLC
  • Jiangsu Hengrui Medicine Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Reata Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • vTv Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll